The Man with "Normal" Testosterone

Presentation

He's 36. Works a physically demanding job, the kind where he's on his feet eight to ten hours, lifting, moving, genuinely working hard. By every external measure, he shouldn't be falling apart. He's not sedentary. He's not eating badly. He's not doing anything obviously wrong.

But over the last two or three years, something has changed. The fatigue now follows him home from work instead of dissipating. His libido has dropped, not absent, but noticeably dimmer than it was. He's been having some difficulty with erections: not a complete problem, but inconsistent in a way that's new. He's noticed that his midsection has thickened despite the same activity level. He tried pushing harder in the gym for a while and it didn't seem to do much.

He went to his primary care doctor. Got labs. The call back was brief: "Everything looks normal." The testosterone was 310 ng/dL. The doctor noted it was within the reference range and moved on.

He's not satisfied with that answer, because the answer doesn't match what he's experiencing in his body. He's right to be unsatisfied.

The Lab Panel. What Was Ordered, What It Showed

Standard primary care panels for complaints like his typically include total testosterone, a basic metabolic panel, and maybe a CBC. What actually came back:

What was not ordered, and what it would have shown had it been:

Reading the Pattern

Here's what's happening, and why none of it showed up in the original workup.

He has visceral obesity, not just a high BMI, but truncal fat, the kind that sits around the organs and is metabolically active in a way that subcutaneous fat is not. Adipose tissue, particularly visceral adipose tissue, contains an enzyme called aromatase. Aromatase converts testosterone to estradiol. The more visceral fat, the more aromatase activity, the more testosterone is being converted to estrogen rather than remaining available as testosterone.

That aromatase activity also does something else: it suppresses SHBG. Sex hormone-binding globulin, the carrier protein for testosterone, is down. When SHBG is low, the free testosterone calculation will trend upward; less binding protein means more unbound hormone mathematically. In this case, the total testosterone is genuinely low at 310 ng/dL, but the suppressed SHBG makes the free testosterone calculate as apparently normal. The lab reports 12.4 pg/mL and flags nothing. The doctor sees it and moves on. The clinical trap is that low SHBG in this setting is not a sign of hormonal health; it's a direct marker of insulin resistance. A low SHBG alongside elevated estradiol and suppressed DHEA-S is the signature of metabolic hypogonadism, not a reassuring finding.

The fasting insulin of 19 µIU/mL is the central driver. His fasting glucose was 96, technically normal. But insulin resistance doesn't show up in fasting glucose until it's advanced. By the time glucose rises, the insulin has been elevated for years. His HOMA-IR of approximately 4.5 indicates meaningful insulin resistance, and that insulin resistance is doing several things simultaneously: driving visceral fat accumulation, suppressing the hypothalamic-pituitary signaling that governs testosterone production, and creating the chronic low-grade inflammation reflected in his hsCRP.

DHEA-S at 82 µg/dL for a 36-year-old is suppressed. DHEA-S, dehydroepiandrosterone sulfate, is an adrenal precursor hormone that contributes to testosterone and estrogen production and has independent effects on energy, mood, and immune function. Suppressed DHEA-S in a younger man often signals chronic stress physiology and adrenal suppression from sustained high cortisol, which is exactly what you'd expect in someone with insulin resistance and poor recovery.

The Two Wrong Answers

There are two easy ways to mismanage this case, and both are common.

Wrong Answer 1: Prescribe testosterone. His total testosterone is low-normal, he has hypogonadal symptoms, so start TRT. This feels logical. It's not. Giving this man exogenous testosterone will suppress his already-impaired hypothalamic-pituitary axis, potentially permanently reducing his endogenous production capacity. It will not address the insulin resistance. It will not correct the elevated aromatase activity, which means the exogenous testosterone will, to a meaningful degree, aromatize to estradiol as well. He may feel somewhat better for a while, but the metabolic root cause will continue advancing, and now he's dependent on a hormone he didn't need to be on in the first place.

Wrong Answer 2: Reassure him everything is fine. This is what happened. It leaves him without a diagnosis, without a treatment plan, and without any understanding of the trajectory his metabolic health is on. Insulin resistance at this stage is not benign and it is not static. Left unaddressed, it progresses toward pre-diabetes, type 2 diabetes, cardiovascular disease, and continued testosterone decline. His symptoms are real and they have a cause. Telling him the labs look normal doesn't make them go away.

The Right Answer

This is a case of metabolic hypogonadism, testosterone suppression secondary to insulin resistance, visceral adiposity, and the downstream hormonal disruption those conditions create. The diagnosis isn't primary hypogonadism (a testicular problem) or secondary hypogonadism in the traditional sense (a pituitary problem). The problem is metabolic, and the treatment should target the metabolic root cause first.

The evidence here is well-established: losing ten percent of body weight in a man with obesity-related hypogonadism raises total testosterone by roughly 100 to 250 ng/dL, without any exogenous hormone. That's the equivalent of moving him from 310 to somewhere between 410 and 560 ng/dL, which lands him solidly in the range where most of his symptoms would be expected to improve. No TRT. No suppression of his endogenous axis. No long-term dependency.

The clinical approach for this man:

GLP-1 agonist therapy. For a man with clear insulin resistance, visceral adiposity, and metabolic dysfunction, GLP-1 receptor agonists (semaglutide or tirzepatide) are the highest-leverage metabolic intervention available. They reduce visceral fat specifically, improve insulin sensitivity, lower systemic inflammation, and produce the kind of weight loss that drives testosterone recovery. The data on GLP-1s and metabolic hypogonadism is consistent with the biology.

Structured resistance training. Muscle is insulin-sensitive tissue. Building it improves glucose disposal, reduces visceral fat, improves insulin sensitivity, and supports testosterone directly. This is not a soft lifestyle recommendation; it's a first-line intervention for insulin resistance with a more robust evidence base than most pharmaceuticals in this space.

DHEA supplementation. Given the suppressed DHEA-S, replacing DHEA directly is appropriate, it supports testosterone and estrogen balance, has data for energy and mood, and is inexpensive, safe, and well-tolerated. This is a low-friction intervention that should be in place from the start.

Growth hormone axis support. Once metabolic intervention is underway, peptides like Tesamorelin or Ipamorelin may be appropriate to support body composition improvement and recovery. Tesamorelin specifically has FDA approval and trial data for visceral fat reduction in certain populations, and both peptides improve GH pulsatility without suppressing the endogenous axis. These are later-layer interventions, added once the metabolic foundation is being addressed.

Dietary restructuring. Reducing refined carbohydrate and fructose load, supporting adequate protein intake for muscle retention during weight loss, and timing nutrition around training are all meaningful inputs that compound with everything else.

What This Case Teaches

The metabolic hypogonadism phenotype is common. It's the man who is physically active but metabolically dysfunctional, whose lab numbers sit just inside the reference ranges while his physiology is quietly deteriorating. He gets told he's fine. He knows he isn't.

The lesson isn't that reference ranges are useless, they're useful for what they're designed for. The lesson is that a single number without context is insufficient for clinical decision-making. Total testosterone at 310 tells you one thing. Total testosterone at 310 in the setting of suppressed SHBG, elevated estradiol, elevated fasting insulin, and suppressed DHEA-S tells you something very different.

Good performance medicine is the capacity to read that difference, and to build a protocol around the mechanism, not the number.